The prognostic value of hematogones in patients with acute myeloid leukemia

Chantepie, Sylvain; Parienti, Jean‐Jacques; Salaün, Véronique; Benabed, Khaled; Chèze, Stéphane; Gac, Anne-Claire; Johnson‐Ansah, Hyacinthe; Macro, Margaret; Damaj, Gandhi; Vilque, Jean-Pierre

doi:10.1002/ajh.24350

Cited by 7 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hematogones in bone marrow can be more than 5% when hematopoietic function is activated after chemotherapy in neoplasm patients 12 . A few reports have indicated that the frequency of hematogones in bone marrow could be used as a prognosis indicator of AML, childhood ALL and B-cell ALL patients who have received hematopoietic stem cell transplantation, and suggested a better prognosis when hematogones >1% in childhood ALL 14–18 . However, it has not been thoroughly discussed whether the levels of hematogones and CD34+ myeloblasts in bone marrow have impact on the prognosis for adult ALL patients who have received chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

The prognostic significance of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell lymphoblastic leukemia without minimal residual disease

Liao

Zheng

Jin

et al. 2019

Sci Rep

View full text Add to dashboard Cite

This study was aimed to dissect the prognostic significances of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell acute lymphoblastic leukemia(ALL) without minimal residual disease(MRD) after the induction chemotherapy cycle. A total of 113 ALL patients who have received standardized chemotherapy cycle were analyzed. Cases that were not remission after induction chemotherapy or have received stem cell transplantation were excluded. Flow cytometry was used to quantify the levels of hematogones and CD34+ myeloblasts in bone marrow aspirations, and the patients were grouped according to the levels of these two precursor cell types. The long-term relapse-free survival(RFS) and recovery of peripheral blood cells of each group after induction chemotherapy were compared. The results indicated that, after induction chemotherapy, patients with hematogones ≥0.1% have a significantly longer remission period than patients with hematogones <0.1% (p = 0.001). Meanwhile, the level of hematogones was positively associated with the recovery of both hemoglobin and platelet in peripheral blood, while CD34+ myeloblasts level is irrelevant to the recovery of Hb and PLT in peripheral blood, level of hematogones and long-term prognosis. This study confirmed hematogones level after induction chemotherapy can be used as a prognostic factor for ALL without MRD. It is more applicable for evaluation prognosis than CD34+ myeloblasts.

show abstract

Section: Introductionmentioning

confidence: 99%

The prognostic significance of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell lymphoblastic leukemia without minimal residual disease

Liao

Zheng

Jin

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…and MRD (+) groups in AML patients in one of their study (Chantepie et al, 2016). While the presence of HG in the MRD (À) group provides a better PFS and OS, the presence of HG in the MRD (+) group is provides worse PFS and OS.…”

Section: Discussionmentioning

confidence: 94%

“…While HG was not detected in 31 (38.8%) patients, HG was detected in 49 (61.2%) patients. The median HG value in the HG (+) group was found five (Chantepie et al, 2013;Chantepie et al, 2016;D'Arena et al, 2001;Doki et al, 2015;Greipp et al, 2005;Lúcio et al, 1999;McKenna et al, 2001;McKenna et al, 2004;Moreno-Madrid et al, 2008;Muehleck et al, 1983;Palumbo et al, 2015;Palumbo & Anderson, 2011;Sarmiento Palao et al, 2019;Sevilla et al, 2010). The demographic and clinical characteristics of these two groups are summarized in Table 1.…”

Section: Resultsmentioning

confidence: 99%

“…While the ratio of HG decreases with age, it is known that there is no difference between women and men in terms of HG ratio (Lúcio et al, 1999;McKenna et al, 2001). HGs after chemotherapy have been proven to be successful in predicting early relapse in some diseases such as acute myeloid leukemia (AML) and Acute lymphoblastic leukemia (ALL) (Chantepie et al, 2016;Sarmiento Palao et al, 2019). In addition, in a few recent studies it has been shown that the increased HG level that was observed after allogeneic stem cell transplantion can be used as a prognostic marker in various hematological malignancies (Doki et al, 2015;Honebrink et al, 2012).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prognostic significance of hematogone presence after autologous stem cell transplantation in patients with multiple myeloma

Göçer

Kurtoğlu

2021

Cytometry Part B Clinical

View full text Add to dashboard Cite

Background: Morphologically and immunophenotypically, the number of B-lymphocyte progenitor cells, so-called hematogones increases after chemotherapy and allogeneic stem cell transplantions. It is thought that hematogones can be used as a prognostic marker in these patients. It is aimed to determine the prognostic significance and factors affecting the development of hematogones, which can be seen after autologous stem cell transplantation in multiple myeloma (MM) patients.Methods: This retrospective and single center study includes 80 patients who underwent autologous stem cell transplantation with the diagnosis of MM in our clinic between January 2013 and December 2019. The primary endpoint of the study was the relationship between the presence and rate of hematogone (HG) and progression free survival (PFS) and overall survival (OS). The secondary endpoint was to identify the factors affecting the development of HG.Results: HG was detected in 61.2% of the patients. There was a moderate and positive linear correlation between the amount of stem cells given and HG ratio (r = 0.387, p = 0.000). PFS and OS were significantly shorter in the group with HG (p = 0.000 and p = 0.012).Conclusions: HG positivity after autologous stem cell transplantation was found to be an independent prognostic marker for PFS and OS in patients with MM. There is a positive relationship between the amount of stem cells used during transplantation and the ratio of HG. As the amount of stem cells increases, the ratio of HG increases and when the ratio of HG increases, PFS and OS become shorter.

show abstract

“…14,15 Superior outcome amongst AML patients with higher level of HGs was observed with both overall survival (OS) and relapse-free survival (RFS). 16 In addition, better RFS and OS rates have been associated with emergence or expansion of HGs in patients after hematopoietic stem cell transplantation (HSCT). [17][18][19][20] Despite the prognostic impact of BM HGs in AML attracting attention recently, [14][15][16] far less is known when it comes to acute lymphoblastic leukemia (ALL).…”

Section: Introductionmentioning

confidence: 99%

The prognostic significance of hematogones in childhood B‐cell acute lymphoblastic leukemia

Arabi

Yousefian

Kavosh

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background: Recent studies have demonstrated hematogones (HGs) expansion to be associated with favorable outcomes in hematological diseases, especially in patients with acute myeloid leukemia and patients undergoing hematopoietic stem cell transplantation. Acute lymphoblastic leukemia (ALL) is the most common form of cancer in children. As of now, minimal residual disease (MRD) remains the most compelling independent prognostic factor in childhood ALL. There is need for more prognostic tools for evaluating relapse risk. Procedure:The goal of this study was to assess the prognostic value of HGs on relapsefree survival (RFS) and overall survival (OS) in childhood ALL. In this prospective cohort study, a total of 122 subjects with definitive diagnosis of precursor B lymphoblastic leukemia were evaluated. Flow cytometric HG detection was performed in bone marrow aspirates after induction and consolidation therapy. Results:The median follow-up period of patients was 35.5 ± 9.4 (SD) months. Patients who had at least 1.0% HGs had a significantly better RFS (p = .023). Moreover, univariate and multivariate analyses confirmed that positive HGs were independently associated with longer RFS (unadjusted model: hazard ratio = 0.33, 95% CI = 0.12-0.91, p = .031; adjusted model: hazard ratio = 0.30, 95% CI = 0.11-0.82, p = .020). Conclusions:Along with the role of MRD, our study shows the significance of HGs as an independent prognostic factor. The results indicate the independent prognostic value of HGs on RFS after adjustment for other prognostic factors, and can be beneficial for risk stratification and treatment modifications amongst pediatric B-cell ALL patients.

show abstract

The prognostic value of hematogones in patients with acute myeloid leukemia

Cited by 7 publications

References 29 publications

The prognostic significance of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell lymphoblastic leukemia without minimal residual disease

The prognostic significance of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell lymphoblastic leukemia without minimal residual disease

Prognostic significance of hematogone presence after autologous stem cell transplantation in patients with multiple myeloma

The prognostic significance of hematogones in childhood B‐cell acute lymphoblastic leukemia

Contact Info

Product

Resources

About